Introduction {#S1}
============

Esophageal cancer affects more than 450,000 people worldwide and ranks sixth among all cancers in mortality ^[@R1]^. There are two main subtypes of esophageal cancer---esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC)---each with known risk factors and pathological features. ESCC comprises up to 90% of esophageal cancer cases worldwide, but the incidence of EAC is increasing and has surpassed ESCC in several areas of North America and Europe ^[@R2]^. Despite recent advances in diagnostics and therapeutics, the prognosis for esophageal cancer remains poor---the five-year survival rate is approximately 15 to 25 percent---largely due to late diagnosis and propensity for metastasis ^[@R1]^. With standard therapy still limited to surgical or endoscopic resection and chemoradiation, there is a need to understand better the molecular pathogenesis of esophageal cancer for developing novel biomarkers and targeted therapies.

Like other GI tract cancers, initial studies on molecular mechanisms underlying esophageal cancer have focused on tumor cell-intrinsic features, namely the activation of oncogenes (cyclin D1 and EGFR) and inactivation of tumor suppressor genes (TP53, p120catenin, E-cadherin) ^[@R3]--[@R5]^. Genomic studies have also been informative in both ESCC and EAC ^[@R6],[@R7]^. However, there is accumulating evidence that tumor cell-extrinsic factors are also integral to esophageal tumorigenesis. These factors, which include immune cells, fibroblasts, endothelial cells, perivascular cells, neurons, adipocytes and extracellular matrix (ECM) components, comprise the tumor microenvironment (TME), which is thought to play a role in inhibiting apoptosis, enabling immune evasion, and promoting proliferation, angiogenesis, invasion and metastasis ^[@R8]^.

A deeper understanding of how tumor cell-TME interactions contribute to esophageal tumorigenesis can direct the development of future therapeutic and diagnostic strategies. In this review we will summarize the current literature on various components of the TME in both ESCC and EAC.

Esophageal tumor initiation is associated with environmental exposures and chronic inflammation {#S2}
===============================================================================================

As in several other cancers, esophageal carcinogenesis occurs due to a complex interplay between environmental factors and genetic predisposition. Another common theme in cancer biology is the relationship between inflammation and tumor development ^[@R9]^. In the subtypes of esophageal cancer, both common and unique risk exposures contribute to the generation of inflammation and the transformation of epithelial cells, forming pre-cancerous and eventually cancerous tissue. These specific aspects of tumor initiation in EAC and ESCC are summarized in [Table 1](#T1){ref-type="table"} and will be discussed in more detail below.

Environmental risk factors and chronic inflammation in EAC {#S3}
----------------------------------------------------------

The longstanding model of EAC development involves the exposure of the distal esophageal epithelium to caustic substances, namely refluxed gastric and bile acids (gastroesophageal reflux disease, GERD), which trigger chronic inflammation and the development of intestinal metaplasia (Barrett\'s esophagus, BE), the precursor lesion to EAC. Other toxic exposures, particularly tobacco, can enhance the degree of tissue damage and inflammation. Interestingly, reflux causes both direct esophageal injury ^[@R10],[@R11]^, as well as the production of reactive oxygen species (ROS) ^[@R12],[@R13]^. Direct injury is thought to lead to intestinal metaplasia by two potential mechanisms. First, aberrant Sonic hedgehog (SHH) signaling between the injured epithelium and adjacent stroma triggers transcription of genes responsible for columnar metaplasia ^[@R14]^. Second, damage to the existing esophageal epithelium can actually make way for migration of epithelial cells from the forestomach, which have a columnar morphology ^[@R15]^. On the other hand, ROS production causes direct DNA damage leading to tumor-initiating mutations ^[@R16]^. Infiltrating inflammatory cells also produce ROS to support the transformation of epithelial cells ^[@R17]^. Furthermore, ROS can activate a number of cancer-associated signaling pathways such as PI3K/Akt, ERK1/2, and NF-κB ^[@R13],[@R18]^. Notably, the presence of both endogenous and exogenous anti-oxidants has been shown to have a protective effect against development of BE and EAC ^[@R19]--[@R21]^.

A risk factor unique to EAC is obesity. This association was assumed previously to be related to GERD in the setting of increased intra-abdominal pressure from central adiposity; however, recently, obesity has been linked to increased risk for several other cancers, indicating that it may promote carcinogenesis through mechanisms other than the purely biomechanical consequences of excess body weight ^[@R22]^. One premise is that obesity may constitute a state of chronic inflammation: adipocyte hypertrophy in obesity can cause hypoxia, which leads to infiltration of activated macrophages into adipose tissue and ultimately induces a pro-inflammatory state with the systemic release of cytokines like interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) ^[@R23]^. These cytokines are involved in anti-apoptotic pathways and transcription of oncogenes, respectively, and have been implicated in esophageal cancer ^[@R24],[@R25]^. Furthermore, alteration of adipokine (leptin and adiponectin) signaling has been associated with GI malignancies ^[@R26]^. In BE, increased leptin levels are associated with an elevated risk for EAC, while higher levels of adiponectin were inversely related to EAC. Adipokine receptors such as ObR (leptin receptor) and AdipR2 (adiponectin) are also upregulated in EAC and may correlate with tumor stage and nodal involvement ^[@R27],[@R28]^. Interestingly, while leptin promotes tumor formation by inhibition of apoptosis and stimulation of cell proliferation via Akt, mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription (STAT) pathways ^[@R29]^, adiponectin seems to have anti-inflammatory vasculo-protective effects driven largely by suppression of IL-6 ^[@R30]^. Thus, both local (GERD) and systemic (obesity) induction of inflammation can lead to EAC development.

Environmental risk factors and chronic inflammation in ESCC {#S4}
-----------------------------------------------------------

Although less studied, chronic inflammation is important also for ESCC development, as demonstrated by elevated inflammatory biomarkers, particularly C-reactive protein (CRP), in ESCC ^[@R31]^. Additionally, several well-known risk factors for ESCC, such as smoking and alcohol ^[@R2]^, cause chronic irritation of the esophageal epithelium and subsequent inflammation via direct toxic effect and production of ROS ^[@R32],[@R33]^. Notably alcohol exposure is a risk factor associated with ESCC, but not EAC. Dietary deficiencies (i.e. low fruits and vegetables) and diet itself (as measured by dietary inflammatory index), especially with high red meat and processed food intake, have also been associated with ESCC development via inflammatory mechanisms ^[@R34],[@R35]^. Moreover, certain rare clinical syndromes known to carry increased risk for ESCC, such as *tylosis palmaris et plantaris* and Plummer-Vinson syndrome, are thought to lead to esophageal dysplasia and later ESCC via chronic inflammation ^[@R36]^. Altogether, this chronic inflammation can trigger the development of esophageal squamous dysplasia and eventually ESCC.

Role of the microbiome in chronic inflammation {#S5}
----------------------------------------------

The GI tract normally contains commensal bacteria (the microbiome) that live in concert with host cells. Disruption of this relationship, termed dysbiosis, may lead to GI carcinogenesis by disrupting epithelial barriers, triggering inflammation, and inducing subsequent DNA damage or pro-oncogenic signaling ^[@R15]^. The role of microbiota in the esophagus has not been as deeply characterized as that in the distal GI tract; however, some evidence suggests that it may have a role in esophageal carcinogenesis, especially in EAC. First, both esophagitis and BE are characterized by alterations in the esophageal microbiome ^[@R37]^, specifically a significant decrease in Gram(+) bacteria and increase in Gram(−) bacteria ^[@R38]^. Gram(−) production of lipopolysaccharide (LPS) leads to inflammation (via Toll-like receptor 4 and NF-κB activation) and increased reflux (via iNOS-mediated relaxation of the lower esophageal sphincter) ^[@R39]^. Furthermore, analogous to *Helicobacter pylori* in gastric carcinogenesis, *Campylobacter spp*. may have a role in causing toxin-mediated inflammation that leads to esophageal cancer ^[@R40]^. Interestingly, *H. pylori* itself may actually provide a protective effect against EAC ^[@R41]^.

Inflammatory signaling pathways promote cell proliferation and survival {#S6}
=======================================================================

A major mechanism by which inflammation induces esophageal carcinogenesis is by constitutive activation of inflammatory signaling pathways ^[@R42]^. Induction of these pathways leads to downstream activation of gene transcription and enzymatic activity that play a key role in tumor growth and survival. Two of the primary pathways implicated in esophageal carcinoma will be discussed here.

Interleukin-6/STAT3 {#S7}
-------------------

The IL-6/STAT3 signaling pathway is upregulated in several cancers ^[@R43]^, including esophageal ^[@R44]^. IL-6 is a cytokine that signals via association of its receptor (IL-6Rα) with gp130, which triggers downstream recruitment and activation of several molecules (SHP2, Ras-MAPK, and PI3K) and notably the STAT1 and STAT3 transcription factors ^[@R45]^. In normal physiology, the IL-6/STAT3 pathway allows normal cells to survive in highly toxic inflammatory environments created by the immune system to kill pathogens; however, in carcinogenesis, this pathway is hijacked by neoplastic cells to promote growth, survival, angiogenesis, and metastasis ^[@R46]^. Interestingly, STAT3 signaling is often constitutively activated in cancer, a phenomenon that not only suppresses apoptosis but also inhibits anti-tumor immunity ^[@R47]^.

Several studies have correlated increased epithelial IL-6/STAT3 activity with cell proliferation and apoptotic resistance in BE and EAC ^[@R48]--[@R50]^. Furthermore, evidence from mouse models and human tissues suggests that exposure to bile acid and low pH induces this pathway in the esophagus ^[@R15],[@R51]^. In fact, *in vitro* exposure of Seg-1 cells (EAC cell line) to a bile acid cocktail and pH of 4 increased IL-6 secretion and activated STAT3 ^[@R51]^. Also, in the *L2-IL-1β* mouse model of BE/EAC, exposure to bile acids accelerated development of BE and EAC by an IL-6 dependent mechanism, with failure of carcinogenesis in the setting of IL-6 deficiency ^[@R15]^. In addition, patients with EAC had higher serum levels of IL-6 than normal controls ^[@R52]^, and increased serum IL-6 was associated with progression from BE to EAC ^[@R53]^. IL-6 is also one of the primary inflammatory mediators produced by adipose tissue and thus may be important in obesity-related inflammation ^[@R54]^.

In ESCC, several studies have reported increased expression of IL-6, IL-6Rα, and STAT3 *in vitro* and in ESCC patients ^[@R25],[@R55],[@R56]^. Moreover, high serum levels and tumor expression of IL-6 correlate with a poor prognosis in ESCC patients receiving neoadjuvant chemoradiotherapy ^[@R57]--[@R60]^, while overexpression of STAT3 similarly indicated a poor prognosis in those who had undergone surgical resection ^[@R61]^. Mechanistically, IL-6 has been shown to drive expansion of pro-tumorigenic myeloid-derived suppressor cells (MDSCs) ^[@R60],[@R62]^, while STAT3 activation leads to production of anti-apoptotic molecules like myeloid cell differentiation protein-1 (Mcl-1) ^[@R55]^.

Recent evidence indicates that the IL-6/STAT3 pathway is an actionable target. First, siRNA-mediated IL-6 inhibition in ESCC cell lines resulted in enhanced chemosensitivity and increased cell death, decreased angiogenesis and less epithelial-to-mesenchymal transition (EMT) ^[@R59],[@R63]^. Furthermore, inhibition of STAT3 signaling by small molecules like stattic radio-sensitized ESCC cells *in vivo* ^[@R64]^. Stattic also induced apoptosis in BE and EAC cells and restored chemo- and radio-sensitivity ^[@R65],[@R66]^.

Nuclear factor-kappaB {#S8}
---------------------

Nuclear factor-kappaB (NF-κB) is a family of structurally related transcription factors that regulate important cell functions like survival, proliferation, and cytokine production. Under normal conditions, NF-κB is maintained in an inactive state by the binding of inhibitory IκB protein ^[@R67]^. Following stimulation by environmental insults such as oxidative or inflammatory stimuli, chemotherapy or radiation, proteasomal degradation of IκB leads to release of NF-κB dimers and translocation to the nucleus, where they activate transcription of critical genes involved in tumorigenesis, immune evasion and treatment resistance ^[@R67],[@R68]^. NF-κB is overexpressed in many liquid and solid tumors, including both EAC and ESCC ^[@R69]^. Activation of this mechanism is thought to be a key link between an inflammatory microenvironment and cancer development ^[@R68]^.

In BE and EAC, bile and gastric acid induce NF-κB expression in esophageal epithelial cells and may enhance cell survival ^[@R70],[@R71]^. NF-κB is also postulated to have a role in cell cycle regulation, as it was found to spatially co-localize and be dually upregulated with cyclin D1 in EAC ^[@R72]^. Interestingly, NF-κB overexpression was specific to BE and EAC, but not reflux esophagitis ^[@R73]^, which suggests that it may be a marker of metaplasia-dysplasia-adenocarcinoma progression rather than simple inflammation. NF-κB was also associated with shortened disease-free and overall survival in patients with EAC ^[@R74]^.

Overexpression of NF-κB has also been noted in ESCC. Previously our laboratory showed increased NF-κB expression in the p120-catenin conditional knockout mouse model of ESCC ^[@R75]^. Other *in vitro* studies on ESCC have shown activation of NF-κB signaling by modulation of upstream mediators, such as upregulation of the transcription factor Id-1 (inhibitor of differentiation/DNA binding) and downregulation of the tumor suppressor Nkx2-8 ^[@R76],[@R77]^. NF-κB activation in these settings led to resistance to TNF-α induced apoptosis and angiogenesis ^[@R76],[@R77]^. As in EAC, NF-κB overexpression was also associated with a poor prognosis in ESCC ^[@R78]^.

Two major downstream effectors of NF-κB involved in esophageal carcinoma are IL-8 and IL-1β. IL-8, also known as CXCL-8, is a chemokine best known for its neutrophil chemotactic properties. However, it has recently been implicated in breast, lung, prostate, and pancreatic cancers, where it had effects on angiogenesis, survival, tumor cell stemness, migration, metastasis, and immune cell infiltration ^[@R79],[@R80]^. IL-1β is a pro-inflammatory cytokine (known to also be a potent inducer of NF-κB) that is abundantly secreted at tumor sites, where it promotes invasiveness, tumor-mediated immune suppression, cancer stem cell self-renewal ^[@R81],[@R82]^. Expression of both of these inflammatory mediators has been demonstrated in esophageal carcinogenesis. For instance, the bile acid deoxycholic acid (DCA) was shown to induce IL-8 expression via NF-κB activation in esophageal cells *in vitro* ^[@R71]^, and this expression was directly correlated with progression to BE and EAC. Meanwhile, elimination of reflux via Nissen fundoplication led to a decrease in IL-8 expression ^[@R83]^. Furthermore, both IL-8 and IL-1β were elevated in BE and markedly elevated in EAC, and overexpression was localized to the site of tumorigenesis ^[@R73],[@R84]^. In ESCC, IL-8 was associated with tumor progression, metastasis, inflammation, and poor prognosis in ESCC patients ^[@R85]^.

As with STAT3, blocking NF-κB activity enhances sensitivity of esophageal cancer cells to paclitaxel ^[@R86]^ and 5-fluorouracil ^[@R87]^. Curcumin, a plant-derived anti-NF-κB compound (interestingly, the STAT3 inhibitor stattic was derived from curcumin), suppresses the esophageal inflammatory response to bile and acid in BE and EAC ^[@R88]^. In addition, inhibition of IL-8 and IL-1β reduces tumor invasiveness as well as tumor-induced immunosuppression ^[@R81]^.

Cyclooxygenase-2 {#S9}
----------------

Although STAT3 and NF-κB converge on several common targets, cyclooxygenase-2 (COX-2) is particularly prominent in esophageal carcinogenesis. COX-2 is an inflammatory enzyme that is responsible for the production of prostaglandin E(2), which has been implicated in GI cancer-related inflammation ^[@R89]^. COX-2 expression is induced by exposure to bile acids ^[@R13],[@R90]^, and its levels are elevated in BE and EAC ^[@R91]^. Studies in ESCC tissues have revealed a positive correlation between COX-2 expression and the degree of dysplasia ^[@R92]^. High COX-2 expression in ESCC was also associated with poor prognosis and chemotherapy resistance ^[@R93]^.

COX-2 inhibitors have shown potential in esophageal cancer. Several studies have demonstrated that both selective and nonselective COX-2 inhibitors suppress inflammation and cell growth while inducing apoptosis in BE and EAC ^[@R94]--[@R96]^. Furthermore, chronic intake of NSAIDs is associated with a decreased incidence of EAC, suggesting a role in prevention as well ^[@R96]^. In ESCC, COX-2 inhibition leads to decreased cell proliferation, PGE2 production and overall tumor progression *in vitro* and *in vivo* ^[@R92]^. It should be noted that STAT3 and NF-κB are not simply parallel pathways but actually have a complex, interdependent relationship. In fact, NF-κB/IL-6/STAT3 are thought to form a self-sustaining positive feedback loop for signal amplification ^[@R97]^. Additionally, STAT3 and NF-κB share several downstream effectors, exemplifying redundancy that enhances the resilience of cancer cells even if one of these pathways is inhibited ^[@R98]^.

Immune modulation promotes tumor evasion and survival {#S10}
=====================================================

Tumor escape from anti-tumor immunity is critical for tumor survival and progression. Tumor cells can suppress the anti-tumor immune response via recruitment of various immune cell populations or expression of inhibitory molecular factors ([Figure 1](#F1){ref-type="fig"}). The specific cell types and factors implicated in esophageal cancer will be discussed below.

Myeloid-derived suppressor cells {#S11}
--------------------------------

Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that play a key role in immune suppression and other tumor-promoting processes, such as fibroblast activation and angiogenesis ^[@R99]^. Activation and expansion of MDSCs are triggered by inflammation, namely pro-inflammatory molecules like IL-1β, IL-6, and PGE2 ^[@R100],[@R101]^, as well as other tumor-secreted factors like VEGF ^[@R102]^. MDSCs suppress anti-tumor immunity by several mechanisms---direct inhibition of T cell activation ^[@R103]^, inhibition of NK cell cytotoxicity ^[@R104]^, depletion of the amino acids arginine and cysteine ^[@R105]^, and the induction of regulatory T cells ^[@R106]^. The notion that MDSCs have a role in tumor progression is supported by several animal models ^[@R107]^. In fact, our laboratory showed that MDSCs were greatly expanded in the p120-catenin deficient mouse model of ESCC and could activate fibroblasts to induce desmoplasia ^[@R75]^. Furthermore, elevated levels of MDSCs were observed in esophageal cancer patients and were associated with advanced disease, a poor prognosis and therapeutic resistance ^[@R60],[@R108]^.

MDSCs present a therapeutic challenge because of their heterogeneous nature. In an effort to better define the factors that mark and drive MDSC-mediated immunosuppression in esophageal cancer, we recently demonstrated that MDSCs with greater immunosuppressive and pro-tumorigenic capacity express high levels of CD38 ^[@R62]^. CD38 expression was driven by factors such as IL-6, IFN-γ, TNF-α, IGFBP-3 and CXCL16, and crosslinking of CD38 with a monoclonal antibody daratumumab (now FDA-approved for treatment of multiple myeloma ^[@R109]^) decreased esophageal tumor growth *in vivo* ^[@R62]^. Importantly, the expansion of CD38-positive MDSCs was also found in the peripheral blood of advanced stage cancer patients ^[@R62]^. Certainly, further investigation into MDSC biology, particularly the functions of various subsets of this population, will provide direction for therapeutic development.

Regulatory T cells {#S12}
------------------

Regulatory T cells (Tregs) also possess immunosuppressive capacity in cancer. In normal physiology, Tregs regulate the expansion and activation of B and T cells, as well as NK cell cytotoxicity; however, in cancer they suppress anti-tumor immune responses ^[@R110]^. Interestingly, Tregs may have a dual role in tumorigenesis, initially suppressing inflammation that leads to carcinogenesis, but later attenuating anti-tumor immunity via mechanisms such as the secretion of immunosuppressive cytokines, interference with tumor-associated antigen presentation and inhibition of cytotoxic cell function and granule release ^[@R111]^.

Expansion of Tregs has been noted both in the peripheral blood and esophageal mucosa of esophageal cancer patients (relative to healthy donors) ^[@R112],[@R113]^. Increased recruitment of Tregs in esophageal cancer, particularly ESCC, is at least partially mediated by the chemokines CCL17 and CCL22, which are secreted by tumor cells and macrophages to recruit Tregs via the CCR4 receptor ^[@R114]^. Furthermore, Treg infiltration was found to have prognostic significance, with higher amounts of Tregs associated with deeper tumor invasion ^[@R115]^, metastasis ^[@R116]^, overall disease severity ^[@R117]^, and decreased survival post-chemotherapy ^[@R118]^. In addition, a recent report on esophageal cancer patients receiving neoadjuvant chemoradiation showed that the density of Tregs in the residual tumor (post-treatment) was correlated not only with pathological response but also with cancer-specific survival ^[@R119]^. A number of strategies for interfering with Treg differentiation, recruitment, and function have been outlined previously ^[@R111]^. Like MDSCs, however, Tregs are heterogeneous and possess several context-dependent functions that are not well-characterized, presenting a challenge for the field.

Th-17 cells {#S13}
-----------

Th17 cells are a subset of T-helper cells more recently implicated in tumor immunomodulation. As such, their precise role in regulating tumor immunity is still being debated ^[@R120]^. In some cases, Th17 cells seem to have anti-tumor properties, while in others they appear to promote tumor growth through suppression of anti-tumor immunity ^[@R121]^. For instance, when cultured with the cytokines TGF-β and IL-6, Th17 cells express the ectonucleotidases CD39 and CD73, which release adenosine, leading to CD8+ T cell suppression ^[@R122]^. Th17 cells also possess the capacity to convert into Tregs ^[@R123]^. Furthermore, through secreted cytokines such as IL-17 and IL-22, Th17 cells can also induce angiogenesis and promote tumor growth via STAT3 activation ^[@R121]^.

There is some evidence supporting Th17 cell involvement in esophageal cancer. Increased proportions of Th17 cells have been observed in the peripheral blood and tumor tissues of EAC and ESCC patients, and the degree of Th17 infiltration was correlated with disease stage ^[@R124],[@R125]^. However, the significance of Th17 cells in cancer remains controversial, and the factors that influence Th17 behavior are not currently well defined ^[@R120],[@R121]^. Thus, there is a clear need for a deeper understanding of the role of Th17 cells in esophageal cancer to determine its potential as a therapeutic target.

Programmed death-1 {#S14}
------------------

There has recently been increased interest in other immunosuppressive mechanisms, particularly immune checkpoints like the programmed cell death protein 1 (PD-1) pathway. PD-1 is a negative co-stimulatory receptor that is part of the CD28 family, expressed primarily on activated T cells ^[@R126]^. Upon engagement with its ligands, programmed cell death ligand 1 or 2 (PD-L1 or PD-L2), PD-1 inhibits T cell activation ^[@R127]^. These ligands can be expressed by tumor cells, immune cells (i.e. macrophages), and endothelial cells to suppress T-cell mediated tumor immunity ^[@R128]^.

In esophageal cancer, multiple studies have reported elevated expression of both PD-L1 and PDL2 ^[@R129],[@R130]^. In fact, increased expression of either PD-L1 or PD-L2 in cancer cells was associated with decreased survival in ESCC patients ^[@R129]^, and increased PD-L1 expression was correlated with greater depth of tumor invasion and worse survival in ESCC ^[@R130]^. Interestingly, only PD-L2 expression was correlated with decreased CD8+ T cell infiltration ^[@R129]^. Additionally, a recent study demonstrated increased expression of PD-L2 in BE and EAC, with a weaker relationship in PD-L1 ^[@R126]^. The increase in PD-L2 expression was induced by pro-tumorigenic Th2 cytokines such as IL-4/IL-13 ^[@R126]^. This evidence suggests that PD-1 blocking agents, which have shown promise in melanoma, renal and lung cancer ^[@R131]^, may have utility in esophageal cancer.

Tumor-associated macrophages {#S15}
----------------------------

Tumor-associated macrophages (TAMs) facilitate a variety of pro-tumorigenic mechanisms. Macrophages exist on a phenotypic spectrum, ranging from an M1 to M2 state: whereas M1 represents "classically" activated macrophages that produce type I pro-inflammatory cytokines, present antigens, fight infections and have anti-tumor qualities, M2 macrophages produce type II cytokines and have many pro-tumorigenic attributes ^[@R132]^. M2 polarization can be induced by hypoxia as well as via activation of the COX-2/PGE2 pathway ^[@R89],[@R107],[@R133]^. Once M2-polarized, TAMs produce growth factors and proteases that enhance tumor initiation, invasion, angiogenesis, metastasis, and immunosuppression ^[@R107],[@R134]^. Interactions between macrophages and epithelial cells play a critical role in esophageal carcinogenesis. In a rat model of reflux esophagitis, M1 macrophages recruited to the inflammation site activated the STAT3 pathway in epithelial and stromal cells, promoting subsequent M2 macrophage polarization and progression to both ESCC and EAC ^[@R135]^. Furthermore, in tissues obtained from EAC patients, tumor cell upregulation of Th2 cytokines like IL-4 and IL-13 promoted M2 macrophage infiltration, which was associated with MDSC-mediated immunosuppression ^[@R136]^. In ESCC patients, increased secretion of tumor-derived macrophage chemoattractant protein-1 (MCP-1) resulted in TAM infiltration and production of angiogenic enzymes like thymidine phosphorylase ^[@R137]^. TAM infiltration was also associated with poor responses to chemotherapy and overall poor prognosis in ESCC ^[@R138]^.

Stromal components and signaling facilitate tumor progression {#S16}
=============================================================

Cancer-associated fibroblasts {#S17}
-----------------------------

Many cancers, including esophageal cancer, are derived from chronic injury and inflammation---wounds that do not properly heal. Unsurprisingly, cells that normally respond to injury, such as fibroblasts, have a prominent role in the initiation, progression, and eventual spread of tumors. Indeed, there is substantial evidence that a specific subset of fibroblasts, called cancer-associated fibroblasts (CAFs), are integral to all stages of cancer ^[@R139]^. CAFs have an activated phenotype---marked by expression of proteins like fibroblast activation protein-α (FAP) and α-smooth muscle actin (α-SMA)---that is thought to be induced by factors like transforming growth factor-β (TGF-β), secreted by cancer cells ^[@R139]^. Recent studies have also implicated miRNAs in the conversion of fibroblasts to CAFs ^[@R140]^, a finding that has been corroborated in ESCC ^[@R141]^. Once in this state, CAFs can modulate the TME by communicating with tumor and other stromal cells via secreted factors, activating pro-inflammatory pathways, disrupting immune surveillance and altering the extracellular matrix (ECM) ([Figure 2](#F2){ref-type="fig"}) ^[@R107],[@R139]^.

Fibroblasts have been shown to play a critical role in esophageal cancer, especially ESCC. In fact, we previously showed that activated fibroblasts promote ESCC cell invasion in a 3-D organotypic cell culture (OTC) model system ^[@R142]^, via the secretion of hepatocyte growth factor (HGF) ^[@R143]^. Furthermore, our lab demonstrated that in the p120-catenin knockout mouse model of ESCC, invasion by tumor cells was accompanied by a marked desmoplastic reaction due to activation of fibroblasts in the tumor stroma by infiltrating MDSCs ^[@R75]^. Our findings have been supported by a number of other studies. For example, several *in vitro* studies in ESCC cell lines have reported that cancer cell proliferation, angiogenesis, and mobility are largely dependent on the presence of activated fibroblasts ^[@R144],[@R145]^. Moreover, the presence of CAFs in ESCC patients was associated with increased microvessel density, increased TAMs, and EMT, which is vital to cancer progression and metastasis ^[@R146]^. CAFs were also associated with poor 3-year survival and disease recurrence after chemoradiation ^[@R147]^. Further investigation showed that irradiation led to increased expression of HGF and β-catenin by fibroblasts, with concomitant downregulation of E-cadherin in co-cultured ESCC cells, indicating a more invasive phenotype ^[@R148]^.

CAFs are involved in EAC as well. Hayden et al. observed that CAF conditioned media supported EAC cell growth despite the presence of cisplatin and 5-FU and led to a twofold increase in EAC cell invasion in OTC compared to normal fibroblast conditioned media ^[@R149]^. Meanwhile, Underwood et al. found that the vast majority of EAC cases (93%) contained activated CAFs in resected esophageal tissue, with absence of CAFs associated with improved survival ^[@R150]^.

Transforming growth factor-β {#S18}
----------------------------

Transforming growth factor-β (TGF-β) signaling regulates tumor initiation, progression and metastasis ^[@R151]^. Classically, TGF-β family ligands bind the extracellular domain of the TGF-β receptor, which triggers downstream activation of canonical Smad protein signaling, leading to transcription of genes important for tissue homeostasis, neoplastic growth and progression ^[@R151]^. Interestingly, TGF-β signaling appears to have a dual role in regulating tumorigenesis: in early stages it is a growth suppressor, but later it promotes EMT and metastasis ^[@R151],[@R152]^.

This dual role has been described in both EAC and ESCC. Early in esophageal carcinogenesis, TGF-β signaling appears to have an inhibitory effect on tumor growth, with both EAC and ESCC cell lines showing decreased TGF-β responsiveness via downregulation of Smad4 or TGF-β-resistant c-Myc expression ^[@R153]^. Consistent with this, Smad4 expression was progressively decreased in the metaplasia-dysplasia-adenocarcinoma sequence of EAC with recovery of the antiproliferative response upon Smad4 restoration ^[@R154]^. Interestingly, ESCC-specific studies have had mixed findings. Whereas TGF-β downregulation by DACH1 methylation or decreased Smad4 expression were associated with increased depth of invasion, later tumor stage and poor differentiation ^[@R155],[@R156]^, TGF-β downregulation by proteasomal degradation actually suppressed growth and invasion *in vivo* ^[@R157]^. Still, ESCC patient studies have supported a tumor-suppressive role for TGF-β, with decreased signaling correlated with more aggressive tumor characteristics and a worse prognosis ^[@R158]^.

Later in tumorigenesis, TGF-β seems to have a pro-tumorigenic effect. This "switch" is thought to be mediated largely by the loss of adaptor proteins, which are required for proper control of TGF-β tumor suppressor function. For example, β2-spectrin (β2-SP) is an adaptor protein that plays an essential role in cell-cell interactions and maintenance of epithelial cell polarity. In EAC, loss of β2-SP in tumor cells led to increased expression of SOX9 and c-Myc but reduced expression of other TGF-β targets like E-cadherin and the cell-cycle regulators p21 and p27 ^[@R159]^. TGF-β signaling also triggers fibroblast activation, which also contributes to tumor invasion, angiogenesis, and EMT ^[@R144]^. Together, these changes allow TGF-β to promote tumor progression and eventual metastasis via EMT. In fact, in both EAC and ESCC, increased TGF-β signaling is associated with advanced tumor stage, metastasis, and treatment resistance ^[@R160],[@R161]^.

Hepatocyte growth factor {#S19}
------------------------

Hepatocyte growth factor (HGF), also known as scatter factor, is a growth factor involved in embryogenesis and organ regeneration and wound healing in adults. By binding its tyrosine kinase receptor c-Met, HGF induces the activation of oncogenic signaling pathways and facilitates invasion, angiogenesis and scattering of cells leading to metastasis ^[@R162]^. Importantly, overexpression of HGF has been noted in both ESCC and EAC as compared to non-dysplastic tissues ^[@R163]--[@R165]^. HGF overexpression has also been correlated with decreased survival, poor differentiation, depth of tumor invasion, pathologic stage, metastasis and recurrence ^[@R165],[@R166]^.

Several studies have highlighted the mechanisms by which HGF promotes tumor progression. To start, we previously showed that fibroblast-derived HGF was essential for tumor cell invasion of the ECM in an organotypic culture model of ESCC ^[@R143]^. Both fetal esophageal fibroblasts (FEFs) and ESCC-derived CAFs secreting HGF were able to promote invasion of EPC-hTERT-EGFR-p53^R175H^ (genetically transformed primary esophageal cells) cells, TE12 and TE7 cells, whereas HGF-deficient fibroblasts did not promote invasion ^[@R143]^. Moreover, siRNA and pharmacological inhibition of HGF/c-Met signaling each prevented invasion ^[@R143]^. Interestingly, radiation exposure, a known risk factor for ESCC, induced fibroblasts to increase secretion of HGF, leading to enhanced growth, invasion, EMT and metastasis *in vitro* ^[@R167]^. Additionally, HGF was shown to upregulate VEGF expression and promote angiogenesis in ESCC ^[@R164],[@R168]^. In EAC, upregulation of HGF/c-Met signaling led to increased PI3K/Akt pathway activation, decreased E-cadherin, and increased β-catenin signaling ^[@R169]^.

Vascular endothelial growth factor {#S20}
----------------------------------

Angiogenesis is generally accepted as a key mechanism of continued survival and progression in solid tumors, and has been shown to play a role in both ESCC and EAC ^[@R170],[@R171]^. A key mediator of angiogenesis is vascular endothelial growth factor (VEGF), which comprises a family of structurally similar proteins that primarily trigger endothelial cells to proliferate, migrate, and break down the extracellular matrix to establish new vessels ^[@R172]^. Both tumor and stromal cells, notably fibroblasts, secrete active VEGF under the influence of environmental conditions such as hypoxia ^[@R173]^. Accordingly, a significant subset (30-60%) of esophageal carcinomas have increased VEGF-A expression ^[@R174]--[@R176]^, though several studies have suggested that VEGF-A upregulation has prognostic significance in only ESCC ^[@R175],[@R176]^. Several studies have also confirmed that VEGF-C, a lymphangiogenic factor, is associated with survival, tumor depth, stage, and lymph node metastasis in ESCC ^[@R177],[@R178]^. In EAC, there is evidence of progressively increasing VEGF-A expression in the metaplasia-dysplasia-adenocarcinoma sequence, with more advanced cancers showing still higher levels ^[@R179],[@R180]^.

Stromal cell-derived factor-1 {#S21}
-----------------------------

In addition to growth factors, fibroblasts also secrete chemokines, particularly stromal cell-derived factor-1 (SDF-1), also known as CXCL12 ^[@R139]^. Binding of SDF-1 to its receptors CXCR4 and CXCR7 on tumor cells has been shown to induce tumor cell growth, promote angiogenesis, stimulate motility and invasiveness, and recruit tumor cells to metastatic sites ^[@R181]^.

SDF-1/CXCR4/CXCR7 expression has been noted in both ESCC and EAC ^[@R182],[@R183]^, and activity of this axis is associated with survival as well as tumor invasion and metastasis ^[@R182]^, though independent analyses of each of these components as prognostic indicators have yielded inconsistent results ^[@R183]--[@R185]^. Nonetheless, in EAC, SDF-1 was shown to mediate the migration of CXCR4-positive tumor cells *in vitro* and *in vivo*, where daily stimulation by SDF-1 led to the dose-dependent development of liver, lung, peritoneal and retroperitoneal metastases in NMRI/nu mice ^[@R186]^. In ESCC, siRNA knockdown of CXCR4 suppressed proliferation, invasion, and metastasis of KYSE-150 and TE-13 cell lines *in vitro* and *in vivo* ^[@R187]^.

Extracellular matrix remodeling {#S22}
-------------------------------

Extracellular matrix (ECM) remodeling is thought to play a key role in tumor formation and progression, particularly invasion ^[@R188]^. Fibroblasts and other stromal cells secrete ECM remodeling enzymes, such as lysyl oxidase (LOX) and matrix metalloproteinases (MMPs), which contribute to formation of a primary tumor or metastatic niche and downregulation of cellular adhesion to enable invasion, migration, and intravasation ^[@R189],[@R190]^. ECM remodeling has been implicated in esophageal cancer, especially ESCC. For example, LOX-L2 was overexpressed in over 90% of ESCCs ^[@R191]^. In addition, several matrix metalloproteinases (MMPs), including MMP-2, MMP-7, and MMP-9, were upregulated in ESCC and associated with tumor stage ^[@R192],[@R193]^. MMPs like MMP-1 and MMP-7 may also have a role in progression of BE to EAC ^[@R194],[@R195]^. Interestingly, several MMPs are known to be downstream of STAT3 and NF-κB signaling ^[@R192],[@R196]^.

Several molecular components of the ECM have also been reported to be important in supporting tumor progression. For example, our laboratory previously showed that periostin (POSTN), a matricellular protein secreted by fibroblasts in response to TGF-β ^[@R188]^, cooperates with mutant p53 to induce STAT1 activation and facilitate ESCC cell invasion ^[@R197]^. Intriguingly, both shRNA-mediated knockdown of POSTN and restoration of wildtype p53 decreased STAT1 activation and tumor invasion *in vivo* ^[@R197]^. OTC-based investigation of POSTN in EAC yielded similar results, with downregulation of POSTN leading to total loss of EAC cell invasion ^[@R149]^. Other ECM components have also been implicated, particularly in ESCC. Fibronectin (FN), for example, is an ECM glycoprotein that is upregulated in ESCC and associated with depth of tumor invasion ^[@R198]^. In addition, the proteoglycan dermatan sulfate (DS) was increased five-fold in human biopsies of ESCC ^[@R199]^. Subsequent study of DS *in vitro* showed that knockdown of iduronic acid, a component of DS, led to decreased migration and invasion of ESCC cells and was correlated with decreased HGF binding and pERK1/2 activity ^[@R199]^. Lastly, hyaluronan (HA), a glycosaminoglycan in the ECM with pro-tumorigenic properties, has been shown to be upregulated in the stroma surrounding ESCC tissues, especially in tumors with significant desmoplasia ^[@R200]^. Importantly, inhibition of HA synthesis by either 4-methylumbelliferone or lentiviral knockdown of HA-synthase suppressed tumor progression and promoted a more differentiated phenotype in ESCC xenografts ^[@R201]^.

Perspectives {#S23}
============

Targeting the TME in esophageal cancer {#S24}
--------------------------------------

A number of observations have highlighted the TME as a potential therapeutic target. First, cells within the TME are much more genetically stable than cancer cells, with less selection pressure, fewer mutations, and a lower chance of developing resistance. Furthermore, because they cannot rely on genetic mutations to drive behavior, cells in the TME are highly dependent on factors in their environment for their pro-tumorigenic features. Consequently, they can be manipulated by disrupting environmental factors and other interactions that drive functional changes observed in tumorigenesis.

The TME frequently provides a tumor-protective niche that contributes to treatment resistance. For example, the ability to blunt responses to conventional chemoradiation was a common function among several of the TME components in esophageal cancer. On the whole, disruption of these components in preclinical studies restored sensitivity to chemoradiation, suggesting considerable promise for TME-directed therapeutics in combination with tumor cell-directed agents. This combinatorial approach is now being explored in several clinical trials ([Table 2](#T2){ref-type="table"}). To date, the most popular treatment approaches in esophageal cancer targeting the TME generally include inhibition of angiogenesis (anti-VEGF) or immune checkpoint blockade (PD-1, CTLA-4)---both potential options for treatment of esophageal cancer due to their availability and early promise in other solid malignancies. TME-targeting treatment approaches specific to individual subtypes of esophageal cancer---analogous to targeting human epidermal growth factor receptor-2 (HER2) in EAC over ESCC, since HER2 gene amplification is far more common in EAC ^[@R202]^---have not yet been pursued, but further identification of differential factors uniquely important to each subtype may reveal more specific strategies. One possibility would be to target the stromal compartment of the TME (i.e. CAFs and ECM components) specifically in ESCC, which has a stronger association with desmoplasia and more evidence showing the upregulation of these factors in tumor progression.

Still, certain characteristics of the TME can make effective intervention quite challenging. For instance, the TME has the paradoxical capacity to both promote and impede tumor growth and progression. Additionally, despite relative genetic stability, the TME contains cell populations that are quite plastic and heterogeneous in nature. What is more, there are likely important differences between the microenvironments of different cancers ^[@R142],[@R203]^, and even a single cancer\'s microenvironment likely changes in response to the tumor\'s mutational landscape or simply during different stages of disease.

These characteristics can make targeting the TME quite challenging. There are strategies to potentially overcome this heterogeneity, however. For example, because the TME possesses both pro-tumor and anti-tumor capabilities, identifying the specific drivers of each of these behaviors could allow for reprogramming of the cells in the TME to actively impair tumor progression ^[@R107]^. This strategy has been explored in cell populations like TAMs, where various agents from receptor inhibitors to miRNAs have been used to re-polarize TAMs into M1-like macrophages ^[@R204],[@R205]^. Another method for combating heterogeneity involves identifying subsets of cell populations that are predominant drivers of protumorigenic behavior, as we demonstrated with CD38^high^ MDSCs. A third approach for overcoming this complexity is to identify and target factors involved in the crosstalk between cells---that is, targeting cell- cell interactions rather than cells directly. Several of the factors reviewed here, such as IL-6 and TGF-β, fall into this category. Certainly, continued efforts identifying novel TME interactions and characterizing context-dependent variations in the TME will lead to refinement of these treatment approaches.

Future horizons {#S25}
---------------

Recent efforts to characterize the TME in esophageal cancer have provided a glimpse into the vast landscape of cell types and factors that contribute to esophageal carcinogenesis. However, considering recent findings in other cancers, there are areas of TME research in esophageal cancer that will likely evolve in the coming years. First, we anticipate that the mechanism by which risk factors (i.e. obesity) predispose to esophageal cancer will be better characterized. In fact, recent studies in other cancers have implicated fibroblast activation, increased ECM stiffness, and altered gut microbiota as ways by which obesity can lead to malignancy ^[@R206],[@R207]^. Furthermore, there are relatively nascent areas of TME research yet to be explored in esophageal cancer. For example, a recent study in gastric cancer showed that tumor growth could be inhibited by blocking cholinergic signaling, demonstrating the presence of a "neural niche" for gastric tumorigenesis ^[@R208]^. Lastly, there remains a need for further elucidation of factors in the TME that could potentially drive the divergence of EAC and ESCC. For example, it is possible that risk factors unique to EAC (i.e. GERD and obesity) create a microenvironment that specifically contributes to the development of EAC (and not ESCC), and we imagine that continued study will reveal mediators---such as cytokines and chemokines---that may be differentially important for each subtype of esophageal cancer. In the end, it is likely that a complex, dynamic interaction between cell of origin and microenvironment leads to the divergence of these subtypes, despite arising in the same organ. Importantly, a better understanding of the idiosyncrasies of the TME in EAC versus ESCC could have broad implications for the treatment and prevention of each of these cancers.

Conclusions {#S26}
-----------

In this review, we have discussed several of the major cell populations, molecular factors, and signaling pathways of the TME that have been studied specifically in ESCC and EAC ([Fig. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). The TME is intricately involved in all stages of tumorigenesis, from creating a niche for initial development to modulating immune function, promoting angiogenesis, and inducing metastasis. Going forward, it will be critical to gain further insights into what defines and drives the heterogeneity of the TME. Understanding how the TME promotes each subtype of esophageal cancer, how specific TME components alter response to therapy, and how the TME adapts to different tumor oncogenic profiles will also be key. Despite tremendous variability and certain differences, however, there is still a great deal of similarity between the different TMEs. As we have shown here, many risk factors, pathways, signaling factors, and cell types are conserved among EAC and ESCC. Ultimately, insights into both similarities and differences of TMEs from various cancer types will be crucial for the future development of TME-targeted therapies, as well as determining who should receive them. In the case of esophageal cancer, progress in these areas will hopefully lead to improved treatment options and better outcomes for this deadly disease.

![Immune landscape in esophageal cancer\
Several immune cell types disrupt anti-tumor immunity (cytotoxic CD8+ T cells) in the tumor microenvironment (TME). Tregs expressing CCR4 are recruited by chemokines CCL17 and CCL22 that are secreted by tumor cells (and TAMs). Tregs exert immunosuppressive function via direct contact with effector T cells or by molecules such as adenosine or immunosuppressive cytokines (IL-10, IL-35). Th17 cells are stimulated by TGF-β and IL-6 and have the ability to convert into Tregs (dashed line) and release adenosine by ectoenzymatic (CD39, CD73) function. Expansion of myeloid derived suppressor cells (MDSC), or immature myeloid cells, is stimulated by inflammation and tumor-derived factors (i.e. VEGF), and these cells directly inhibit T cell activation and NK cell cytotoxicity, while also inducing Tregs. TAM expansion (M2 polarization) occurs in presence of Th2 cytokines (i.e. IL-4, IL-13), and these cells are recruited via chemokines such as MCP-1. Furthermore, TAMs and tumor cells both express PD-L1/2 to inhibit T cell activation via the PD-1 receptor. Altogether, these cells suppress anti-tumor immunity while also promoting tumor growth and progression by various mechanisms.](nihms-754046-f0001){#F1}

![Stromal compartment of the esophageal TME\
**A.** Neoplastic cells secrete growth factors to activate quiescient fibroblasts designated as cancer associated fibroblasts (CAFs). CAFs can proliferate to contribute to desmoplasia, secreting extracellular matrix (ECM) components such as fibronectin (FN) to enhance the development of the primary tumor niche. CAFs also secrete cytokines that promote tumor cell survival (anti-apoptosis). **B.** Later in tumorigenesis, CAFs remodel the ECM with enzymes like lysyl oxidase (LOX) and matrix metalloproteinases (MMPs) as well as ECM components like dermatan sulfate (DS) and hyaluronan (HA) to promote invasion. CAFs also secrete growth factors that trigger tumor cells to undergo epithelial-mesenchymal transition (EMT) and chemokines that induce tumor cell migration. CAFs can also promote angiogenesis via VEGF secretion.](nihms-754046-f0002){#F2}

###### Elements of tumor initiation in EAC and ESCC

GERD, gastroesophageal reflux disease; HPV, human papilloma virus

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factor                         EAC                                                                              ESCC
  ------------------------------ -------------------------------------------------------------------------------- --------------------------------------------
  **Potential cell of origin**   Esophageal basal progenitor cells (via transdifferentiation or reprogramming)\   Esophageal basal progenitor cells
                                 **and/or**\                                                                      
                                 Gastric cardia progenitor cells (via migration)                                  

  **Precursor lesion**           Intestinal metaplasia (Barrett\'s esophagus)                                     Squamous dysplasia

  **Location**                   Distal third of esophagus                                                        Typically proximal two-thirds of esophagus

  **Risk exposures**             Age\                                                                             Age\
                                 Race (white \> black)\                                                           Race (black \> white)\
                                 Gender (males \> females)\                                                       Gender (males \> females)\
                                 GERD\                                                                            Cigarette smoking (ESCC \> EAC)\
                                 Obesity\                                                                         Alcohol\
                                 Cigarette smoking (EAC \< ESCC)\                                                 Nutritional deficiences\
                                 Diet (high red meat and processed foods; low fruit and vegetables)               HPV infection\
                                                                                                                  Tylosis palmaris et plantaris (inherited)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Clinical trials with agents targeting the esophageal TME

In some cases agents may also target tumor cells directly. Under "molecular target," all agents are inhibitors except for those in parentheses, which are molecular mimics of endogenous agonists. For combinatorial approaches, combined agent is standard chemotherapy unless another agent is specified. CCR4, C-C chemokine receptor 4; CD137, cluster of differentiation antigen 137; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; IL-6, interleukin-6; IL-12, interleukin-12; IL-15, interleukin-15; LAG3, lymphocyte-activation gene 3; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PDGFR, platelet-derived growth factor receptor; SMO, smoothened; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

  TME component           Molecule          Sponsor                                  Molecular Target or (mimic)                         Treatment modality                    Phase
  ----------------------- ----------------- ---------------------------------------- --------------------------------------------------- ------------------------------------- ----------------------
  **Angiogenesis**        Apatinib          Hangzhou Cancer Hospital                 VEGFR-2                                             Single Agent                          II (NCT02544737)
                          Bevacizumab       Dana-Farber Cancer Institute             VEGF-A                                              Combination                           II (NCT01191697)
                                            Fox Chase Cancer Center                                                                      Combination                           II (NCT01212822)
                                            Memorial Sloan Kettering Cancer Center                                                       Combination                           II (NCT00354679)
                                            Vanderbilt University Medical Center                                                         Single Agent (after chemoradiation)   0 (NCT02072720)
                                            Genentech                                                                                    Combination                           I (NCT01633970)
                          Endostar          Jiangsu Simcere Pharmaceutical Co.       VEGFR-2                                             Combination (radiotherapy)            II (NCT01368419)
                          Sunitinib         Roswell Park Cancer Institute            PDGFRs and VEGFRs                                   Combination                           I (NCT00524186)
                          Ziv-aflibercept   Dana-Farber Cancer Institute             VEGF                                                Combination                           II (NCT01747551)
                                                                                                                                                                               
  **Immune checkpoint**   Avelumab          EMD Serono                               PD-L1                                               Single Agent                          I (NCT01772004)
                          BMS-986016        ONO/Bristol-Meyers Squibb                LAG3                                                Combination (nivolumab)               I (NCT01968109)
                          Iplimumab         MD Anderson Cancer Center                CTLA-4                                              Combination (imatinib)                I (NCT01738139)
                          MEDI4736          MedImmune/AstraZeneca                    PD-1                                                Single Agent                          I/II (NCT01693562)
                          MPDL3280A         Roche/Genentech                          PD-1                                                Single Agent                          I (NCT01375842)
                          Nivolumab         ONO/Bristol-Meyers Squibb                PD-1                                                Single Agent                          II (JapicCTI-142422)
                                            Bristol-Meyers Squibb                                                                        Combination (lirilumab)               I (NCT01714739)
                          Pembrolizumab     Merck                                    PD-1                                                Single Agent                          I (NCT02054806)
                          PF-05082566       Pfizer                                   CD137                                               Single Agent                          I (NCT01307267)
                          Urelumab          Bristol-Meyers Squibb                    CD137                                               Single Agent                          I (NCT01471210)
                                                                                                                                                                               
  **Immune (other)**      Mogamulizumab     Aichi Medical University                 CCR4                                                Single Agent                          I (NCT01929486)
                          Siltuximab        Janssen Biotech                          IL-6                                                Single Agent                          I/II (NCT00841191)
                          NHSIL-12          NCI                                      (recombinant IL-12)                                 Single Agent                          I (NCT01417546)
                          rhIL-15           NCI                                      (recombinant IL-15)                                 Single Agent                          I (NCT01572493)
                          Thymalfasin       Hangzhou Cancer Hospital                 (synthetic thymosin alpha-1)                        Combination (radiotherapy)            II (NCT02545751)
                                                                                                                                                                               
  **Stroma/ECM**          LDE225            MD Anderson Cancer Center/Novartis       SMO                                                 Combination (everolimus)              I (NCT02138929)
                                                                                                                                                                               
  **Other**               Thalidomide       Changzhou No. 2 People\'s Hospital       broadly targets vasculature and immune components   Combination                           II (NCT01551641)
